Efficacy and safety of neuroleptics in behavioral disorders associated with dementia

Journal of Clinical Psychiatry

Volumn 59, Issue 10, 1998, Pages 550-561

  Lanctôt, Krista L ^a,b   Best, Tamara S ^a   Mittmann, Nicole ^a,b   Liu, Barbara A ^a   Oh, Paul I ^a,c   Einarson, Thomas R ^a   Naranjo, Claudio A ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETOPHENAZINE DIMALEATE; AMITRIPTYLINE PLUS PERPHENAZINE; AMOBARBITAL; BENZATROPINE; BENZATROPINE MESILATE; BIPERIDEN; BUSPIRONE; CARBAMAZEPINE; CHLORAL HYDRATE; CHLORPROMAZINE; DIAZEPAM; DIPHENHYDRAMINE; HALOPERIDOL; LOXAPINE SUCCINATE; NEUROLEPTIC AGENT; OLANZAPINE; OXAZEPAM; QUETIAPINE; RISPERIDONE; SELEGILINE; THIORIDAZINE; TIOTIXENE; TRAZODONE; TRIFLUOPERAZINE; TRIHEXYPHENIDYL;

AKATHISIA; ANTICHOLINERGIC EFFECT; ARTICLE; BEHAVIOR DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEDATION; SIDE EFFECT; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

EID: 0031756048     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v59n1010     Document Type: Article

References (105)

1. Ostbye T, Crosse E. Net economic costs of dementia in Canada. Can Med Assoc J 1994;151(10):1457-1464
2. Ernst RL, Hay JW. The US economic and social costs of Alzheimer's disease revisited. Am J Public Health 1994;84:1261-1264
3. Canadian Study of Health and Aging Working Group. Canadian study of health and aging: study methods and prevalence of dementia. Can Med Assoc J 1994;150:899-913
4. Teri L, Rabins P, Whitehouse P, et al. Management of behavior disturbance in Alzheimer disease: current knowledge and future direction. Alzheimer Dis Assoc Disord 1992;6(2):77-88
5. Reisberg B, Borenstein J, Salob SP, et al. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry 1987;48 (5, suppl):9-15
6. Raskind MA. Geriatric psychopharmacology: management of late-life depression and the noncognitive behavioral disturbances of Alzheimer's disease. In: Dunner DL, ed. The Psychiatric Clinics of North America: Psychopharmacology II. Philadelphia, Pa: W.B. Saunders Co; 1993:815-827
7. Kunik ME, Yudofsky SC, Silver JM, et al. Pharmacologic approach to management of agitation associated with dementia. J Clin Psychiatry 1994;55(2, suppl):13-17
8. Whall AL, Gillis GL, Yankou D, et al. Disruptive behavior in elderly nursing home residents: a survey of nursing staff. J Gerontol Nurs 1992;18: 13-17
9. Zimmer JG, Watson N, Treat A. Behavioral problems among patients in skilled nursing facilities. Am J Public Health 1984;74:1118-1121
10. Swearer JM, Drachman DA, O'Donnell BF, et al. Troublesome and disruptive behaviors in dementia: relationship to diagnosis and disease severity. J Am Geriatr Soc 1988;36:784-790
11. Cohen-Mansfield J, Billig N. Agitated behaviors in the elderly, I: a conceptual review. J Am Geriatr Soc 1986;34:711-721
12. Ryden MB. Aggressive behavior in persons with dementia who live in the community. Alzheimer Dis Assoc Disord 1988;2:342-355
13. Helms PM. Efficacy of antipsychotics in the treatment of the behavioral complications of dementia: a review of the literature. J Am Geriatr Soc 1985;33:206-209
14. Sunderland T, Silver MA. Neuroleptics in the treatment of dementia. Int J Geriatr Psychiatry 1988;3:79-88
15. Avorn J, Dreyer P, Connelly K, et al. Use of psychoactive medication and the quality of care in rest homes: findings and policy implications of a statewide study. N Engl J Med 1989;320:227-232
16. Lantz MS, Louis A, Lowenstein G, et al. A longitudinal study of psychotropic prescriptions in a teaching nursing home. Am J Psychiatry 1990; 147:1637-1639
17. Raskind MA, Risse SC. Antipsychotic drugs and the elderly. J Clin Psychiatry 1986;47(5, suppl):17-22
18. Risse SC, Barnes R. Pharmacologic treatment of agitation associated with dementia. J Am Geriatr Soc 1986;34:368-376
19. Barnes R, Veith R, Okimoto J, et al. Efficacy of antipsychotic medications in behaviorally disturbed dementia patients. Am J Psychiatry 1982;139: 1170-1174
20. Tune LE, Steele C, Cooper T. Neuroleptic drugs in the management of behavioral symptoms of Alzheimer's disease. Psychiatr Clin North Am 1991;14:353-373
21. Wragg RE, Jeste DV. Neuroleptics and alternative treatments: management of behavioral symptoms and psychosis in Alzheimer's disease and related conditions. Psychiatr Clin North Am 1988;11:195-213
22. Schneider LS, Pollock VE, Lyness SA. A meta-analysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990;38:553-563
23. Einarson T, Leeder S, Koren G. A method for meta-analysis of epidemiological studies. Drug Intell Clin Pharm 1988;22:813-824
24. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188
25. Velanovich V. Meta-analysis for combining Bayesian probabilities. Med Hypotheses 1991;35:192-195
26. Dickersin K, Berlin JA. Meta-analysis: state-of-the-science. Epidemiol Rev 1992;14:154-176
27. Lohr JB, Jeste DV, Harris MJ, et al. Treatment of disordered behavior. In: Salzman C, ed. Clinical Geriatric Psychopharmacology. 2nd ed. Baltimore, Md: Williams & Wilkins; 1992:79-113
28. Breslow NE, Day NE. Statistical methods in cancer research, vol 1: the analysis of case-control studies. IARC Sci Publ 1980;32:5-338
29. World Health Organization Regional Office for Europe. Bergman U, Grimsson A, Wahba AW, et al, eds. Studies on drug utilization: methods and applications. Copenhagen, Denmark: Regional Publications, European Series No. 8, 1979
30. Abse DA, Dahlstrom WG, Hill C. The value of chemotherapy in senile mental disturbances: controlled comparison of chlorpromazine, reserpinepipradrol, and opium. JAMA 1960;174:2036-2042
31. Hamilton LD, Bennett JL. Acetophenazine for hyperactive geriatric patients. Geriatrics 1962;17:596-601
32. Hamilton LD, Bennett JL. The use of trifluoperazine in geriatric patients with chronic brain syndrome. J Am Geriatr Soc 1962;10:140-147
33. Sugarman AA, Williams BH, Adlerstein AM. Haloperidol in the psychiatric disorders of old age. Am J Psychiatry 1964;120:1190-1192
34. Kirven LE, Montero EF. Comparison of thioridazine and diazepam in the control of nonpsychotic symptoms associated with senility: double-blind study. J Am Geriatr Soc 1973;21:546-551
35. Smith GR, Taylor CW, Linkous P. Haloperidol versus thioridazine for the treatment of psychogeriatric patients: a double-blind clinical trial. Psychosomatics 1974;15:134-138
36. Covington JS. Alleviating agitation, apprehension, and related symptoms in geriatric patients: a double-blind comparison of a phenothiazine and a benzodiazepine. South Med J 1975;68:719-724
37. Rada RT, Kellner R. Thiothixene in the treatment of geriatric patients with chronic organic brain syndrome. J Am Geriatr Soc 1976;3:105-107
38. Cowley LM, Glen RS. Double-blind study of thioridazine and haloperidol in geriatric patients with a psychosis associated with organic brain syndrome. J Clin Psychiatry 1979;40:411-419
39. Götestam KG, Ljunghall S, Olsson B. A double-blind comparison of the effects of haloperidol and cis(Z)-clopenthixol in senile dementia. Acta Psychiatr Scand Suppl 1981;suppl 294:46-53
40. Petrie WM, Ban TA, Berney S, et al. Loxapine in psychogeriatrics: a placebo-and standard-controlled clinical investigation. J Clin Psychopharmacol 1982;2:122-126
41. Ather SA, Shaw SH, Stoker MJ. A comparison of chlormethiazole and thioridazine in agitated confusional states of the elderly. Acta Psychiatr Scand Suppl 1986;73(suppl 329):81-91
42. Lovett WC, Stokes DK, Taylor LB, et al. Management of behavioral symptoms in disturbed elderly patients: comparison of trifluoperazine and haloperidol. J Clin Psychiatry 1987;48:234-236
43. Coccaro EF, Kramer E, Zemishlany Z, et al. Pharmacologic treatment of noncognitive behavioral disturbances in elderly demented patients. Am J Psychiatry 1990;147:1640-1645
44. Carlyle W, Ancill RJ, Sheldon L. Aggression in the demented patient: a double-blind study of loxapine versus haloperidol. Int Clin Psychopharmacol 1993;8:103-108
45. Finkel SI, Lyons JS, Anderson RL, et al. A randomized, placebo-controlled trial of thiothixene in agitated, demented nursing home patients. Int J Geriatr Psychiatry 1995;10:129-136
46. Altman H, Mehta D, Evenson RC, et al. Behavioral effects of drug therapy on psychogeriatric inpatients, I: chlorpromazine and thioridazine. J Am Geriatr Soc 1973;21:241-248
47. Ananth JV, Saxena BM, Lehmann HE, et al. Combined administration of thioridazine and nicotinic acid in the treatment of geriatric patients. Curr Ther Res Clin Exp 1971;13:158-161
48. Barton R, Hurst L. Unnecessary use of tranquillizers in elderly patients. Br J Psychiatry 1966;112:989-990
49. Birkett DP, Boltuch B. Chlorpromazine in geriatric psychiatry. J Am Geriatr Soc 1972;20:403-405
50. Boillat JE, Saxena BM, Lehmann HE, et al. Combined administration of thioridazine, nicotinic acid, and fluoxymesterone in the treatment of geriatric patients. Curr Ther Res 1971;13:541-544
51. Branchey MH, Lee JH, Simpson GM, et al. Loxapine succinate as a neuroleptic agent: evaluation in two populations of elderly psychiatric patients. J Am Geriatr Soc 1978;26:263-267
52. Brenner HD, Alberti L, Keller F, et al. Pharmacotherapy of agitational states in psychiatric gerontology: double-blind study: febarbamat-pipamperon. Neuropsychobiology 1984;11:187-190
53. Cahn LA, Diesfeldt HF. The use of neuroleptics in the treatment of dementia in old age: a critical analysis with reference to an experiment with a long-acting oral neuroleptic. Psychiatr Neurol Neurochir 1973;76:411-420
54. Chouinard G, Pinard G, Serrano M, et al. Potentiation of haloperidol by alpha-methyldopa in the treatment of schizophrenic patients. Curr Ther Res 1973;15:473-483
55. Cook WA. Methylperidol: clinical trials of a new tranquillizer. Med J Aust 1966;2:117-119
56. Danto BL. Triflupromazine versus pentylenetetrazol-nicotinic acid for treatment of chronic brain disease on a general-hospital psychiatric service. J Am Geriatr Soc 1969;17:414-420
57. DeCuyper H, van Praag HM, Verstraeten D. The effect of milenperone on the aggressive behavior of psychogeriatric patients: a double-blind placebo-controlled study. Neuropsychobiology 1985;13:1-6
58. Devanand DP, Sackeim HA, Brown RP, et al. A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer's disease. Arch Neurol 1989;46:854-857
59. Fuglum E, Schillinger A, Anderson JB, et al. Zuclopenthixol and haloperidol/levomepromazine in the treatment of elderly patients with symptoms of aggressiveness and agitation: a double-blind, multi-centre study. Pharmatherapeutica 1989;5:285-291
60. Ganzini L, Heintz R, Hoffman WF, et al. Acute extrapyramidal syndromes in neuroleptic-treated elders: a pilot study. J Geriatr Psychiatry Neurol 1991;4:222-225
61. Goldstein SE, Birnbom F. Piperacetazine versus thioridazine in the treatment of organic brain disease: a controlled double-blind study. J Am Geriatr Soc 1976;24:355-358
62. Goldstein SE. The use of mesoridazine in geriatrics. Curr Ther Res 1974; 16:316-323
63. Grünberger J, Saletu B, Linzmayer L, et al. Clinical-pharmacological study with the two isomers (d-,1-) of fenfluramine and its comparison with chlorpromazine and d-amphetamine: psychometric and psychophysiological evaluation. Methods Find Exp Clin Pharmacol 1993;15:313-328
64. Judah L, Murphree O, Seager L. Psychiatric response of geriatric-psychiatric patients to Mellaril (TP-21 Sandoz). Am J Psychiatry 1959;115: 1118-1119
65. Lehmann HE, Ban TA, Saxena BM. Nicotinic acid, thioridazine, fluoxymesterone and their combinations in hospitalized geriatric patients: a systematic clinical study. Can Psychiatr Assoc J 1972;17:315-320
66. Nygaard H, Brudvik E, Lien GK, et al. Zuclopenthixol and melperon in the treatment of elderly patients: a double-blind, controlled, multi-centre study. Pharmatherapeutica 1987;5:152-158
67. Nygaard HA, Bakke K, Brudvik E, et al. Dosing of neuroleptics in elderly demented patients with aggressive and agitated behaviour: a double-blind study with zuclopenthixol. Curr Med Res Opin 1994;13:222-231
68. Phanjoo AL, Link C. Remoxipride versus thioridazine in elderly psychotic patients. Acta Psychiatr Scand 1990;82(suppl 358):181-185
69. Robinson DB. Evaluation of certain drugs in geriatric patients: effects of chlorpromazine, reserpine, pentylenetetrazol U.S.P., and placebo on eighty-four female geriatric patients in a state hospital. Arch Gen Psychiatry 1959;1:57-62
70. Seager CP. Chlorpromazine in treatment of elderly psychotic women. Br Med J 1955;1:882-885
71. Steele C, Lucas MJ, Tune L. Haloperidol versus thioridazine in the treatment of behavioral symptoms in senile dementia of the Alzheimer's type: preliminary findings. J Clin Psychiatry 1986;47:310-312
72. Szuba MP, Bergman KS, Baxter LR, et al. Safety and efficacy of high-dose droperidol in agitated patients. J Clin Psychopharmacol 1992;12:144-146
73. ter Haar HW. A comparison of chlormethiazole and haloperidol in the treatment of elderly patients with confusion of organic and psychogenic origin: a double-blind crossover study. Pharmatherapeutica 1977;1: 563-569
74. ter Haar HW. The relief of restlessness in the elderly. Age Ageing 1977;(suppl 6):73-77
75. Tewfik GI, Jain VK, Harcup M, et al. Effectiveness of various tranquilizers in the management of senile restlessness. Gerontol Clin (Basel) 1970;12: 351-359
76. Tobin JM, Brousseau ER, Lorenz AA. Clinical evaluation of haloperidol in geriatric patients. Geriatrics 1970;25:119-122
77. Tsuang M, Lu LM, Stotsky BA, et al. Haloperidol versus thioridazine for hospitalized psychogeriatric patients: double-blind study. J Am Geriatr Soc 1971;19:593-600
78. Vangtorp A, Simmelsgaard H, Mellegaard M. Experience with a new butyrophenone derivative (Buronil). Acta Psychiatr Scand Suppl 1968;203: 235-238
79. Viukari M, Salo H, Lamminsivu U, et al. Tolerance and serum levels of haloperidol during parenteral and oral haloperidol treatment in geriatric patients. Acta Psychiatr Scand 1982;65:301-308
80. Cole JL, Goldberg SC, Klerman GL. Phenothiazine treatment in acute schizophrenia. Arch Gen Psychiatry 1960;10:246-261
81. Davis JM, Schaffer CB, Killian GA, et al. Important issues in the drug treatment of schizophrenia. Schizophr Bull 1980;6:70-87
82. Baldessarini RJ. Antipsychotic agents. In: Baldessarini RJ, ed. Chemotherapy in Psychiatry: Principles and Practice. Cambridge, Mass: Harvard University Press; 1985:14-92
83. Nilsson K, Palmstierna T, Wistedt B. Aggressive behaviour in hospitalized psychogeriatric patients. Acta Psychiatr Scand 1988;78:172-175
84. Yudofsky SC, Silver JM, Hales RE. Pharmacologic management of aggression in the elderly. J Clin Psychiatry 1990;51(10, suppl):22-28
85. McDonald WM, Krishnan KRR. Pharmacologic management of the symptoms of dementia. Ann Fam Physician 1990;42:123-132
86. Colenda CC. Drug treatment of behavior problems in elderly patients with dementia, part 2. Drug Ther 1991;July:45-51
87. Eimer M. Management of the behavioral symptoms associated with dementia. Prim Care 1989;16:431-450
88. Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders: a Nordic multicentre study. Br J Psychiatry 1990;157:894-901
89. Olafsson K, Jorgensen S, Jensen HV, et al. Fluvoxamine in the treatment of demented elderly patients: a double-blind, placebo-controlled study. Acta Psychiatr Scand 1992;85:453-456
90. Dehlin O, Hedenrud B, Jansson P, et al. A double-blind comparison of alaproclate and placebo in the treatment of patients with senile dementia. Acta Psychiatr Scand 1985;71:190-196
91. Lawlor BA, Radcliffe J, Molchan SE, et al. A pilot placebo-controlled study of trazodone and buspirone in Alzheimer's disease. Int J Geriatr Psychiatry 1994;9:55-59
92. Nyth AL, Gottfries CG, Lyby K, et al. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand 1992;86:138-145
93. Cantillon M, Brunswick R, Molina D, et al. Buspirone vs. haloperidol: a double-blind trial for agitation in a nursing home population with Alzheimer's disease. Am J Geriatr Psychiatry 1996;4:263-267
94. Sultzer DL, Gray KF, Gunay I, et al. A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Am J Geriatr Psychiatry 1997;5:60-69
95. Burke WJ, Roccaforte WH, Wengel SP, et al. L-deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial. J Am Geriatr Soc 1993;41:1219-1225
96. Lott AD, McElroy SL, Keys MA, et al. Valproate in the treatment of behavioral agitation in elderly patients with dementia. J Neuropsychiatry Clin Neurosci 1995;7:314-319
97. Lemke MR. Effect of carbamazepine on agitation in Alzheimer's inpatients refractory to neuroleptics. J Clin Psychiatry 1995;56:354-357
98. Greendyke RM, Kanter DR, Schuster DB, et al. Propranolol treatment of assaultive patients with organic brain disease: a double-blind crossover, placebo-controlled study. J Nerv Ment Dis 1986;174:290-294
99. Greendyke RM, Berkner JP, Webster JC, et al. Treatment of behavioral problems with pindolol. Psychosomatics 1989;30:161-165
100. Madhusoodanan S, Brenner R, Araujo L, et al. Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. J Clin Psychiatry 1995;56:514-518
101. Lee H, Cooney JM, Lawlor BA. The use of risperidone, an atypical neuroleptic, in Lewy body disease. Int J Geriatr Psychiatry 1994;9:415-417
102. Allen RL, Walker Z, D'Ath PJ, et al. Risperidone for psychotic and behavioural symptoms in Lewy body dementia [letter]. Lancet 1995; 346:185
103. Thompson SG, Pocock SJ. Can meta-analysis be trusted? Lancet 1991; 338:1127-1130
104. Colenda CC. Drug treatment of behavior problems in elderly patients with dementia, part 1. Drug Ther 1991;June:15-18, 20
105. Treatment of agitation in older persons with dementia: Expert Consensus Guidelines. Postgrad Med 1998; Spec No.:1-88